biostudies-literatureHaddad ACCR NIH HHSNCI NIH HHS1021-1032https://www.ebi.ac.uk/biostudies/studies/S-EPMC11773633biostudies-literatureUnknown32(2)<h4>Background</h4>Carcinoembryonic antigen (CEA) levels may vary with administration and discontinuation of pre-hepatectomy chemotherapy in patients undergoing resection of colorectal cancer liver metastases (CLM). The prognostic significance of these changes, termed CEA dynamics, is unclear.<h4>Patients and methods</h4>Consecutive patients undergoing hepatectomy for CLM (2001-2021) at a comprehensive cancer center were included. CEA dynamics were classified as CEA normal (CEA < 5 ng/mL before, during, and after chemotherapy), CEA decrease (elevated CEA levels that drop during and after chemotherapy), and CEA rebound (elevated CEA levels that drop during chemotherapy but rebound upon discontinuation). Recurrence-free (RFS), hepatic-specific disease-free (hDFS), and overall survival (OS) wAnnals of surgical oncologyCEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.PMC11773633P30CA016672P30 CA016672Chun YSMaki HNewhook TEVauthey JNTzeng CDHaddad AUppal ATran Cao HSWang YAyabe RILendoire MFolkert IfalseCEA Rebound After Discontinuation of Pre-Hepatectomy Chemotherapy Predicts Worse Outcomes After Resection of Colorectal Cancer Liver Metastases.<h4>Background</h4>Carcinoembryonic antigen (CEA) levels may vary with administration and discontinuation of pre-hepatectomy chemotherapy in patients undergoing resection of colorectal cancer liver metastases (CLM). The prognostic significance of these changes, termed CEA dynamics, is unclear.<h4>Patients and methods</h4>Consecutive patients undergoing hepatectomy for CLM (2001-2021) at a comprehensive cancer center were included. CEA dynamics were classified as CEA normal (CEA < 5 ng/mL before, during, and after chemotherapy), CEA decrease (elevated CEA levels that drop during and after chemotherapy), and CEA rebound (elevated CEA levels that drop during chemotherapy but rebound upon discontinuation). Recurrence-free (RFS), hepatic-specific disease-free (hDFS), and overall survival (OS) w2025-01-01T00:00:00Z2025 Feb2025-04-04T20:57:03.722Z2025-04-04T20:57:03.722ZS-EPMC117736333951641610.1245/s10434-024-16370-x